In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

House Republicans subpoenaed Pfizer’s former Vice President and Chief Scientific Officer of RNA and Viral Vaccines Dr. Philip Dormitzer. The House Judiciary Committee requested in May that Dormitzer ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) to include patients 12 years of age and ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...